Esperion Therapeutics Inc (ESPR) 13.76 $ESPR
Esperion Therapeutics to Present at BioCentury Future Leaders in the Biotech Industry Conference
Business Wire - Mon Mar 24, 7:08AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion's president and chief executive officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry conference in New York City. The presentation and webcast will take place on Friday, March 28, 2014 at 2:30 p.m. Eastern Time.
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Mar 05, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and reported its financial results for the fourth quarter and full year ended Dec. 31, 2013.
Esperion Therapeutics to Provide ETC-1002 Program Update; Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Feb 26, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host a conference call and webcast to provide program development updates and discuss financial results for the fourth quarter and full year ended Dec. 31, 2013. The webcast will take place following NASDAQ Market close on Wednesday, March 5, 2014 at 4:30 p.m. Eastern Time.
Esperion Therapeutics, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:58PM CST
Pure Multi-Family REIT LP ("Pure Multi"
(TSXV: RUF.U) announced today that the Board of Directors of Pure Multi-Family REIT (GP) Inc., the governing general partner of Pure Multi, has approved a cash distribution of US$0.03 per unit for the month of February 2013 (equivalent to US$0.36 per unit on an annualized basis). The distribution will be paid on March 15, 2013 to unitholders of record at the close of business on February 28, 2013.
Esperion Therapeutics Names Mark E. McGovern, M.D., FACC, FACP, Director
Business Wire - Thu Feb 13, 7:05AM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Mark E. McGovern, M.D., FACC, FACP, as a Director. Dr. McGovern will serve as a Class I director with a term of office expiring at the 2014 annual meeting of stockholders.
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Esperion Therapeutics Inc elects Dr Antonio M. Gotto Jr as director
M2 - Tue Jan 14, 6:11AM CST
Biopharmaceutical company Esperion Therapeutics Inc (NasdaqGM:ESPR) revealed on Monday the addition of Dr. Antonio M. Gotto Jr, MD, DPhil as its director.
Esperion Therapeutics Announces the Appointment of Antonio M. Gotto Jr., M.D., DPhil, as Director
Business Wire - Mon Jan 13, 7:00AM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Antonio M. Gotto Jr., M.D., DPhil as a Director of the Company. Dr. Gotto will serve as a Class II director with a term of office expiring at our 2015 annual meeting of stockholders.
United Kingdom Quarterly Beverage Tracker Report Q22013
PR Newswire - Tue Jan 07, 8:57AM CST
Reportbuyer.com just published a new market research report:
Esperion Therapeutics Added to the NASDAQ Biotechnology Index
Business Wire - Mon Dec 23, 3:05PM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on December 23, 2013. The Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market(R) (NASDAQ(R)) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). This is the most recent index to which the company has been added in 2013. The company is also included in the Russell Global, 3000, 2000, and Microcap indices, and the MSCI Global Micro Cap indices.
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 16, 7:05AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.
Hyperglycemia - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/tlz435/hyperglycemia) has announced the addition of the "Hyperglycemia - Pipeline Review, H2 2013" report to their offering. 'Hyperglycemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperglycemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperglycemia. The analysis is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Hyperglycemia. - A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hyperglycemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Hyperglycemia Overview Therapeutics Development Companies Involved in Hyperglycemia Therapeutics Development Drug Profiles - RLY-106 - Oligotide - Insumera - Sodium Glucose Co-Transporter 1 Inhibitors - KR-62980 - ZLN-005 - ESP-41091 Featured News & Press Releases Appendix Companies Mentioned - Esperion Therapeutics, Inc. - GENTIUM S.p.A. - Kissei Pharmaceutical Co., Ltd. - PhaseBio Pharmaceuticals, Inc. - Relypsa, Inc. For more information visit http://www.researchandmarkets.com/research/tl...erglycemia
Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance
Business Wire - Mon Nov 18, 7:00AM CST
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced full results of a Phase 2 clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance. The study, ETC-1002-006, met its primary endpoint, demonstrating that ETC-1002 significantly lowered LDL-C compared to placebo by an average of 32 percent and was well tolerated. The data were presented today in an oral presentation at the 2013 Scientific Sessions of the American Heart Association in Dallas by principal investigator Paul D. Thompson, M.D. Esperion previously announced positive topline results from this study in June 2013.
Esperion Therapeutics Announces Oral Presentation on ETC-1002 at 2013 Scientific Sessions of the American Heart Association
Business Wire - Mon Nov 11, 3:05PM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that full results of the Phase 2 ETC-1002-006 clinical study in patients with hypercholesterolemia and a history of statin intolerance will be presented in an oral presentation session by principal investigator Paul D. Thompson, M.D., on November 18 at the 2013 Scientific Sessions of the American Heart Association in Dallas. Later in the day, the Company will webcast a briefing of the results.
Hyperlipidemia - Pipeline Review, H2 2013
M2 - Thu Nov 07, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/j5fl49/hyperlipidemia) has announced the addition of the "Hyperlipidemia - Pipeline Review, H2 2013" report to their offering. 'Hyperlipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperlipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperlipidemia. Scope - A snapshot of the global therapeutic scenario for Hyperlipidemia. - A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hyperlipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Eli Lilly and Company Tekmira Pharmaceuticals Corp. Isis Pharmaceuticals, Inc. Samyang Corporation Daewoong Pharmaceutical Co., Ltd. Dr. Reddy's Laboratories Limited Santaris Pharma A/S Idera Pharmaceuticals, Inc. Yuhan Corporation Regeneron Pharmaceuticals, Inc. Immuron Limited Hanall Pharmaceutical Co., Ltd. Ahn-Gook Pharmaceutical Co., Ltd. Catabasis Pharmaceuticals, Inc. aRigen Pharmaceuticals, Inc. Esperion Therapeutics, Inc. FORMAC Pharmaceuticals N.V. For more information visit http://www.researchandmarkets.com/research/j5...rlipidemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Esperion Therapeutics Reports Third Quarter 2013 Financial Results and Provides Development Program Updates
Business Wire - Wed Nov 06, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today provided development program updates and reported its financial results for the third quarter ended September 30, 2013.
Esperion Therapeutics to Present at Credit Suisse Healthcare Conference
Business Wire - Tue Nov 05, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion's president and chief executive officer, will present at the Credit Suisse Healthcare Conference in Scottsdale, Ariz. The presentation will take place on Tuesday, November 12, at 8 a.m. MST/11:00 a.m. EST.
Esperion Therapeutics Announces Initiation of Phase 2b Clinical Study of ETC-1002 in Patients With or Without Statin Intolerance and Hypercholesterolemia
Business Wire - Wed Oct 30, 3:05PM CDT
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced dosing of the first patient in a Phase 2b clinical study of ETC-1002, its lead product candidate, in patients with or without statin intolerance and hypercholesterolemia. The goals of this study, ETC-1002-008, are to compare the LDL-C lowering efficacy of ETC-1002 with ezetimibe and to demonstrate comparable tolerability to ezetimibe, a common therapy for statin intolerance, in the treatment of patients with elevated LDL-C levels. To be considered statin intolerant for ETC-1002-008, a patient must be intolerant to two or more statins, at least one of which was administered at or below the approved starting dose. ETC-1002 is an orally available, once-daily small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.
Esperion Therapeutics to Present at Stifel Nicolaus 2013 Healthcare Conference
Business Wire - Tue Sep 10, 5:55PM CDT
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Roger S. Newton, Ph.D., Esperion's executive chairman, chief scientific officer and company founder, will present at the Stifel Nicolaus 2013 Healthcare Conference in Boston. Dr. Newton's presentation will take place on Wednesday, September 11, at 3:50 p.m. ET at the Four Seasons Hotel.
Esperion Therapeutics to Present at BioCentury Future Leaders in the Biotech Industry Conference
Business Wire - Mon Mar 24, 7:08AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion's president and chief executive officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry conference in New York City. The presentation and webcast will take place on Friday, March 28, 2014 at 2:30 p.m. Eastern Time.
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Mar 05, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and reported its financial results for the fourth quarter and full year ended Dec. 31, 2013.
Esperion Therapeutics to Provide ETC-1002 Program Update; Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Feb 26, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host a conference call and webcast to provide program development updates and discuss financial results for the fourth quarter and full year ended Dec. 31, 2013. The webcast will take place following NASDAQ Market close on Wednesday, March 5, 2014 at 4:30 p.m. Eastern Time.
Esperion Therapeutics, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:58PM CST
Pure Multi-Family REIT LP ("Pure Multi"
(TSXV: RUF.U) announced today that the Board of Directors of Pure Multi-Family REIT (GP) Inc., the governing general partner of Pure Multi, has approved a cash distribution of US$0.03 per unit for the month of February 2013 (equivalent to US$0.36 per unit on an annualized basis). The distribution will be paid on March 15, 2013 to unitholders of record at the close of business on February 28, 2013. Esperion Therapeutics Names Mark E. McGovern, M.D., FACC, FACP, Director
Business Wire - Thu Feb 13, 7:05AM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Mark E. McGovern, M.D., FACC, FACP, as a Director. Dr. McGovern will serve as a Class I director with a term of office expiring at the 2014 annual meeting of stockholders.
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Esperion Therapeutics Inc elects Dr Antonio M. Gotto Jr as director
M2 - Tue Jan 14, 6:11AM CST
Biopharmaceutical company Esperion Therapeutics Inc (NasdaqGM:ESPR) revealed on Monday the addition of Dr. Antonio M. Gotto Jr, MD, DPhil as its director.
Esperion Therapeutics Announces the Appointment of Antonio M. Gotto Jr., M.D., DPhil, as Director
Business Wire - Mon Jan 13, 7:00AM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Antonio M. Gotto Jr., M.D., DPhil as a Director of the Company. Dr. Gotto will serve as a Class II director with a term of office expiring at our 2015 annual meeting of stockholders.
United Kingdom Quarterly Beverage Tracker Report Q22013
PR Newswire - Tue Jan 07, 8:57AM CST
Reportbuyer.com just published a new market research report:
Esperion Therapeutics Added to the NASDAQ Biotechnology Index
Business Wire - Mon Dec 23, 3:05PM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on December 23, 2013. The Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market(R) (NASDAQ(R)) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). This is the most recent index to which the company has been added in 2013. The company is also included in the Russell Global, 3000, 2000, and Microcap indices, and the MSCI Global Micro Cap indices.
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 16, 7:05AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.
Hyperglycemia - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/tlz435/hyperglycemia) has announced the addition of the "Hyperglycemia - Pipeline Review, H2 2013" report to their offering. 'Hyperglycemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperglycemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperglycemia. The analysis is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Hyperglycemia. - A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hyperglycemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Hyperglycemia Overview Therapeutics Development Companies Involved in Hyperglycemia Therapeutics Development Drug Profiles - RLY-106 - Oligotide - Insumera - Sodium Glucose Co-Transporter 1 Inhibitors - KR-62980 - ZLN-005 - ESP-41091 Featured News & Press Releases Appendix Companies Mentioned - Esperion Therapeutics, Inc. - GENTIUM S.p.A. - Kissei Pharmaceutical Co., Ltd. - PhaseBio Pharmaceuticals, Inc. - Relypsa, Inc. For more information visit http://www.researchandmarkets.com/research/tl...erglycemia
Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance
Business Wire - Mon Nov 18, 7:00AM CST
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced full results of a Phase 2 clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance. The study, ETC-1002-006, met its primary endpoint, demonstrating that ETC-1002 significantly lowered LDL-C compared to placebo by an average of 32 percent and was well tolerated. The data were presented today in an oral presentation at the 2013 Scientific Sessions of the American Heart Association in Dallas by principal investigator Paul D. Thompson, M.D. Esperion previously announced positive topline results from this study in June 2013.
Esperion Therapeutics Announces Oral Presentation on ETC-1002 at 2013 Scientific Sessions of the American Heart Association
Business Wire - Mon Nov 11, 3:05PM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that full results of the Phase 2 ETC-1002-006 clinical study in patients with hypercholesterolemia and a history of statin intolerance will be presented in an oral presentation session by principal investigator Paul D. Thompson, M.D., on November 18 at the 2013 Scientific Sessions of the American Heart Association in Dallas. Later in the day, the Company will webcast a briefing of the results.
Hyperlipidemia - Pipeline Review, H2 2013
M2 - Thu Nov 07, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/j5fl49/hyperlipidemia) has announced the addition of the "Hyperlipidemia - Pipeline Review, H2 2013" report to their offering. 'Hyperlipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperlipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperlipidemia. Scope - A snapshot of the global therapeutic scenario for Hyperlipidemia. - A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hyperlipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Eli Lilly and Company Tekmira Pharmaceuticals Corp. Isis Pharmaceuticals, Inc. Samyang Corporation Daewoong Pharmaceutical Co., Ltd. Dr. Reddy's Laboratories Limited Santaris Pharma A/S Idera Pharmaceuticals, Inc. Yuhan Corporation Regeneron Pharmaceuticals, Inc. Immuron Limited Hanall Pharmaceutical Co., Ltd. Ahn-Gook Pharmaceutical Co., Ltd. Catabasis Pharmaceuticals, Inc. aRigen Pharmaceuticals, Inc. Esperion Therapeutics, Inc. FORMAC Pharmaceuticals N.V. For more information visit http://www.researchandmarkets.com/research/j5...rlipidemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Esperion Therapeutics Reports Third Quarter 2013 Financial Results and Provides Development Program Updates
Business Wire - Wed Nov 06, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today provided development program updates and reported its financial results for the third quarter ended September 30, 2013.
Esperion Therapeutics to Present at Credit Suisse Healthcare Conference
Business Wire - Tue Nov 05, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion's president and chief executive officer, will present at the Credit Suisse Healthcare Conference in Scottsdale, Ariz. The presentation will take place on Tuesday, November 12, at 8 a.m. MST/11:00 a.m. EST.
Esperion Therapeutics Announces Initiation of Phase 2b Clinical Study of ETC-1002 in Patients With or Without Statin Intolerance and Hypercholesterolemia
Business Wire - Wed Oct 30, 3:05PM CDT
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced dosing of the first patient in a Phase 2b clinical study of ETC-1002, its lead product candidate, in patients with or without statin intolerance and hypercholesterolemia. The goals of this study, ETC-1002-008, are to compare the LDL-C lowering efficacy of ETC-1002 with ezetimibe and to demonstrate comparable tolerability to ezetimibe, a common therapy for statin intolerance, in the treatment of patients with elevated LDL-C levels. To be considered statin intolerant for ETC-1002-008, a patient must be intolerant to two or more statins, at least one of which was administered at or below the approved starting dose. ETC-1002 is an orally available, once-daily small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.
Esperion Therapeutics to Present at Stifel Nicolaus 2013 Healthcare Conference
Business Wire - Tue Sep 10, 5:55PM CDT
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Roger S. Newton, Ph.D., Esperion's executive chairman, chief scientific officer and company founder, will present at the Stifel Nicolaus 2013 Healthcare Conference in Boston. Dr. Newton's presentation will take place on Wednesday, September 11, at 3:50 p.m. ET at the Four Seasons Hotel.
